Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
An analysis of 122 patients with advanced breast cancer treated with aminoglutethimide was carried out. Forty-one patients (34%) achieved a complete response or partial response (CR + PR), while 81 patients (66%) remained stable or progressed (S + P). A number of variables were analyzed for their prognostic importance in terms of response to aminoglutethimide. These variables were dominant site of metastases, disease-free survival, estrogen receptor status, age, response to prior tamoxifen, response to chemotherapy administered for metastatic disease, and dose of aminoglutethimide. The most important factors in predicting response were found to be prior response to tamoxifen and a longer disease-free survival after diagnosis.
Brufman
G
G
Department of Clinical Oncology, Hadassah University Hospital, Jerusalem, Israel.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D013629:Tamoxifen; D000616:Aminoglutethimide